Literature DB >> 25758602

Survival benefit of TIPS versus serial paracentesis in patients with refractory ascites: a single institution case-control propensity score analysis.

R C Gaba1, A Parvinian2, L C Casadaban2, P M Couture2, S P Zivin3, J Lakhoo2, J Minocha3, C E Ray3, M G Knuttinen3, J T Bui3.   

Abstract

AIM: To compare the impact of covered stent-graft transjugular intrahepatic portosystemic shunt (TIPS) versus serial paracentesis on survival of patients with medically refractory ascites.
MATERIALS AND METHODS: In this retrospective study, cirrhotic patients who underwent covered stent-graft TIPS for refractory ascites from 2003-2013 were compared with similar patients who underwent serial paracentesis during 2009-2013. Demographic and liver disease data, Model for End-Stage Liver Disease (MELD) scores, and survival outcomes were obtained from hospital electronic medical records and the social security death index. After propensity score weighting to match study group characteristics, survival outcomes were compared using Kaplan-Meier statistics with log-rank analysis.
RESULTS: Seventy TIPS (70% men, mean age 55.7 years, mean MELD 15.1) and 80 paracentesis (58% men, mean age 53.5 years, mean MELD 22.5) patients were compared. The TIPS haemodynamic success rate was 100% (mean portosystemic pressure gradient reduction 13 mmHg). Paracentesis patients underwent a mean of 7.9 procedures. After propensity score weighting to balance group features, TIPS patients showed a trend toward enhanced survival compared with paracentesis patients (median survival 1037 versus 262 days, p = 0.074). TIPS conferred a significant increase or trend toward improved survival compared with paracentesis at 1 (66% versus 44%, p = 0.018), 2 (56% versus 38%, p = 0.057), and 3 year (49% versus 32%, p = 0.077) time points. Thirty and 90 day mortality rates were not statistically increased by TIPS.
CONCLUSION: Covered stent-graft TIPS improves intermediate- to long-term survival without significantly increasing short-term mortality of ascites patients, and suggests a greater potential role for TIPS in properly selected ascitic patients when medical management fails.
Copyright © 2015 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25758602     DOI: 10.1016/j.crad.2015.02.002

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  11 in total

1.  Small-diameter TIPS combined with splenic artery embolization in the management of refractory ascites in cirrhotic patients.

Authors:  Nathan E Frenk; Teodora Bochnakova; Suvranu Ganguli; Nathaniel Mercaldo; Andrew S Allegretti; Daniel S Pratt; Kei Yamada
Journal:  Diagn Interv Radiol       Date:  2021-03       Impact factor: 2.630

2.  Chinese guidelines on the management of ascites and its related complications in cirrhosis.

Authors:  Xiaoyuan Xu; Zhongping Duan; Huiguo Ding; Wengang Li; Jidong Jia; Lai Wei; Enqiang Linghu; Hui Zhuang
Journal:  Hepatol Int       Date:  2019-01-18       Impact factor: 6.047

3.  Transjugular intrahepatic portosystemic shunt for the treatment of refractory ascites: A population-based cohort study.

Authors:  Jeffrey M Mah; Maya Djerboua; Patti A Groome; Christopher M Booth; Jennifer A Flemming
Journal:  Can Liver J       Date:  2020-11-17

4.  Clinical Features of Refractory Ascites in Outpatients.

Authors:  Wanda Regina Caly; Rodrigo Martins Abreu; Bernardo Bitelman; Flair José Carrilho; Suzane Kioko Ono
Journal:  Clinics (Sao Paulo)       Date:  2017-07       Impact factor: 2.365

5.  Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis.

Authors:  G Stirnimann; T Berg; L Spahr; S Zeuzem; S McPherson; F Lammert; F Storni; V Banz; J Babatz; V Vargas; A Geier; A Stallmach; C Engelmann; C Trepte; J Capel; A De Gottardi
Journal:  Aliment Pharmacol Ther       Date:  2017-09-21       Impact factor: 8.171

6.  Refractory ascites-the contemporary view on pathogenesis and therapy.

Authors:  Beata Kasztelan-Szczerbinska; Halina Cichoz-Lach
Journal:  PeerJ       Date:  2019-10-15       Impact factor: 2.984

Review 7.  Current management of refractory ascites in patients with cirrhosis.

Authors:  Ruihong Zhao; Juan Lu; Yu Shi; Hong Zhao; Kaijin Xu; Jifang Sheng
Journal:  J Int Med Res       Date:  2017-12-06       Impact factor: 1.671

8.  Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).

Authors:  Thomas Reiberger; Andreas Püspök; Maria Schoder; Franziska Baumann-Durchschein; Theresa Bucsics; Christian Datz; Werner Dolak; Arnulf Ferlitsch; Armin Finkenstedt; Ivo Graziadei; Stephanie Hametner; Franz Karnel; Elisabeth Krones; Andreas Maieron; Mattias Mandorfer; Markus Peck-Radosavljevic; Florian Rainer; Philipp Schwabl; Vanessa Stadlbauer; Rudolf Stauber; Herbert Tilg; Michael Trauner; Heinz Zoller; Rainer Schöfl; Peter Fickert
Journal:  Wien Klin Wochenschr       Date:  2017-10-23       Impact factor: 1.704

Review 9.  Management of refractory cirrhotic ascites: challenges and solutions.

Authors:  Hiroshi Fukui; Hideto Kawaratani; Kosuke Kaji; Hiroaki Takaya; Hitoshi Yoshiji
Journal:  Hepat Med       Date:  2018-07-03

10.  Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension.

Authors:  Dhiraj Tripathi; Adrian J Stanley; Peter C Hayes; Simon Travis; Matthew J Armstrong; Emmanuel A Tsochatzis; Ian A Rowe; Nicholas Roslund; Hamish Ireland; Mandy Lomax; Joanne A Leithead; Homoyon Mehrzad; Richard J Aspinall; Joanne McDonagh; David Patch
Journal:  Gut       Date:  2020-02-29       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.